Placebo followed by Ondansetron — Competitive Intelligence Brief

Placebo followed by Ondansetron (Placebo followed by Ondansetron) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Supportive Care / Antiemetic.

phase 3 5-HT3 receptor antagonist 5-HT3 receptor Supportive Care / Antiemetic Small molecule

Target snapshot

Placebo followed by Ondansetron (Placebo followed by Ondansetron) — University of Colorado, Denver. Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo followed by Ondansetron TARGET	Placebo followed by Ondansetron	University of Colorado, Denver	phase 3	5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Ramosetron, Aprepitant, Dexamethasone	Ramosetron, Aprepitant, Dexamethasone	Hallym University Medical Center	marketed	5-HT3 antagonist / NK1 antagonist / corticosteroid combination	5-HT3 receptor, NK1 receptor, glucocorticoid receptor
Granisetron (Group G)	Granisetron (Group G)	University of Malaya	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Sodium Bicarbonate Powder and ondansetron	Sodium Bicarbonate Powder and ondansetron	Aya Sabry Mohamed Mohamed	marketed	Antacid and antiemetic combination	5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate)
Ondansetron orodispersible film once	Ondansetron orodispersible film once	Chongqing University Cancer Hospital	marketed	5-HT3 receptor antagonist	5-HT3 receptor
ramosetron, ondansetron, dexamethasone	ramosetron, ondansetron, dexamethasone	Government Medical College, Haldwani	marketed	5-HT3 receptor antagonist + corticosteroid combination	5-HT3 receptor (ramosetron, ondansetron); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

1. Helsinn Healthcare SA · 4 drugs in this class
2. LG Life Sciences · 3 drugs in this class
3. University of Malaya · 2 drugs in this class
4. GlaxoSmithKline · 1 drug in this class
5. Hamad Medical Corporation · 1 drug in this class
6. Eye & ENT Hospital of Fudan University · 1 drug in this class
7. Instituto Mexicano del Seguro Social · 1 drug in this class
8. Chongqing University Cancer Hospital · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class
10. MonoSol Rx · 1 drug in this class